©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):63-68, 2026. ISSN: 2550-794X

https://doi.org/10.59298/IDOSRJSR/2026/11.2.6368 IDOSRJSR11106

Nano-Enabled Strategies for Targeting Obesity–Diabetes Crosstalk: Therapeutic Innovations and Clinical Prospects

Taliikwa Nicholas Ceaser

Department of Pharmacognosy Kampala International University Uganda
Email:ceaser.taliikwa@studwc.kiu.ac.ug

ABSTRACT

The intricate link between obesity and diabetes has garnered significant attention, as both conditions are prevalent in modern society and pose considerable public health challenges. A growing body of research suggests that these diseases are closely intertwined, with obesity serving as a major risk factor for the development of type 2 diabetes. Recent advancements in nanotechnology offer promising solutions for tackling the obesity–diabetes crosstalk by enabling precise targeting of underlying pathophysiological mechanisms. This review explores the latest nano-enabled therapeutic strategies aimed at disrupting the interplay between obesity and diabetes, with a focus on innovations in drug delivery, biomolecular modulation, and tissue engineering. Furthermore, the potential of nanomaterials to improve therapeutic efficacy, enhance bioavailability, and reduce side effects will be discussed. The review also highlights clinical prospects and challenges in translating these promising nano-enabled approaches from the laboratory to real-world applications. Given the complexity of both conditions, it is crucial to adopt a multidisciplinary approach that combines nanotechnology with existing therapies to improve patient outcomes. Ultimately, the integration of nanomedicine into clinical practice holds the potential to revolutionize the management of obesity-related diabetes and prevent further escalation of the global diabetes epidemic.

Keywords: Nanomedicine, Obesity, Diabetes, Drug Delivery, Therapeutic Innovation.

INTRODUCTION

Obesity and type 2 diabetes (T2D) have emerged as significant public health concerns worldwide, with an ever-increasing prevalence attributed to sedentary lifestyles, poor dietary habits, and genetic predisposition[1–4]. Both conditions are intimately linked in what is often referred to as the obesity–diabetes crosstalk[5–7]. Obesity, particularly visceral fat accumulation, contributes to insulin resistance, a hallmark of T2D, by promoting chronic low-grade inflammation, altering adipokine secretion, and inducing changes in lipid metabolism. T2D, in turn, accelerates the progression of obesity-related complications, creating a vicious cycle that is difficult to break[6, 8–11]. Traditional therapeutic approaches for managing these conditions have had limited success, often due to issues related to poor drug bioavailability, non-specific targeting, and adverse side effects. As a result, there is a growing need for novel, more effective strategies to address the underlying pathophysiology of both diseases simultaneously.

Nanotechnology, the manipulation of matter at the nanoscale, has emerged as a promising field for developing innovative therapies aimed at overcoming the limitations of conventional treatments[12–15]. Nano-enabled strategies offer several advantages, including enhanced drug delivery, precise targeting, improved bioavailability, and the ability to modulate complex biological pathways with high specificity[16]. In the context of obesity and diabetes, nanomedicine holds tremendous potential for targeted intervention at the molecular, cellular, and tissue levels, which could potentially alter the trajectory of disease progression[17–19]. From lipid-based nanoparticles to biomolecular approaches, nanomaterials can be engineered to modulate insulin sensitivity, reduce adiposity, and regulate glucose metabolism in a controlled and sustained manner. This review aims to provide an in-depth examination of the role of nanotechnology in addressing the obesity–diabetes crosstalk. It will discuss the underlying mechanisms linking obesity and diabetes, the therapeutic strategies currently under investigation, and the clinical prospects for integrating nano-enabled solutions into the

treatment landscape. The review also highlights key innovations in nanomedicine, including drug delivery systems, bioactive nanomaterials, and nanostructured scaffolds for tissue engineering, with a focus on their application in targeting the complex interplay between obesity and diabetes.

Obesity and Diabetes: Pathophysiological Interplay

Obesity and diabetes share numerous pathophysiological mechanisms that contribute to their development and progression. In obesity, excessive caloric intake and sedentary behavior lead to the accumulation of adipose tissue, particularly in the abdominal region[8, 9, 20]. This visceral fat is metabolically active and secretes a variety of pro-inflammatory cytokines, known as adipokines, which include TNF-α, interleukin-6 (IL-6), and resistin. These inflammatory molecules promote insulin resistance by impairing insulin signaling pathways in target tissues, such as muscle, liver, and adipose tissue. Moreover, the excess accumulation of fat leads to the dysregulation of lipid metabolism, with increased circulating levels of free fatty acids (FFAs) that further exacerbate insulin resistance[21–23].

The development of T2D is characterized by a progressive decline in insulin secretion by pancreatic β-cells, coupled with insulin resistance. Insulin resistance leads to hyperglycemia, which, over time, contributes to the dysfunction of various organ systems, including the kidneys, cardiovascular system, and nervous system[24, 25]. Furthermore, both obesity and diabetes are linked to alterations in gut microbiota composition, oxidative stress, and endoplasmic reticulum (ER) stress, all of which contribute to inflammation and insulin resistance. Given the close association between obesity and diabetes, targeting common pathways that mediate their pathophysiological processes is crucial for developing effective therapeutic strategies[26].

Nano-enabled approaches aim to target these underlying molecular mechanisms with precision, offering the potential for more effective treatments. By employing nanoscale drug delivery systems, biomolecular modulation, and tissue-targeted therapies, nanomedicine could provide a means of mitigating the inflammatory response, improving insulin sensitivity, and regulating glucose metabolism, all of which are critical for addressing both obesity and diabetes simultaneously[27, 28].

Nanotechnology in Obesity and Diabetes Therapy

Nanotechnology offers a range of therapeutic innovations that can address the multifactorial nature of obesity and diabetes. One of the key challenges in treating these conditions is the difficulty in achieving precise and sustained drug delivery to specific tissues[13, 17, 19, 27]. Traditional therapies often fail to reach their intended targets, leading to suboptimal therapeutic outcomes. Nanomedicine, however, provides an opportunity to overcome this challenge by designing drug delivery systems that can selectively release therapeutic agents at the site of action[29, 30]. For example, lipid-based nanoparticles and polymeric nanoparticles can be engineered to encapsulate drugs such as insulin, GLP-1 agonists, or anti-inflammatory agents, ensuring their controlled release over time. These nanoparticles can be designed to target specific tissues, such as adipose tissue or the pancreas, where they can modulate insulin sensitivity, reduce inflammation, or stimulate β-cell regeneration[31–33]. Additionally, nanoparticles can be functionalized with targeting ligands that enhance their specificity for particular receptors or cells involved in the obesity–diabetes crosstalk.

Another promising approach involves the use of nanomaterials to modulate adipogenesis, the process by which pre-adipocytes differentiate into mature adipocytes. Nanoparticles can be used to deliver small molecules or siRNA that inhibit the expression of key genes involved in adipocyte differentiation, thereby reducing adiposity and improving insulin sensitivity[34–36]. Furthermore, nanomaterials can be used to enhance the bioavailability and stability of bioactive compounds, such as polyphenols, which have been shown to possess anti-inflammatory, anti-obesity, and anti-diabetic properties.

The potential of nanotechnology to address the obesity–diabetes crosstalk lies in its ability to combine multiple therapeutic strategies within a single nanosystem. By incorporating agents that target inflammation, improve glucose metabolism, and regulate adiposity, nanomedicine has the potential to offer more comprehensive and effective treatments for patients with obesity-related diabetes.

Targeted Drug Delivery Systems: Precision Therapeutics for Obesity–Diabetes

Targeted drug delivery is one of the most promising applications of nanotechnology in the treatment of obesity and diabetes. Traditional drug delivery systems often fail to achieve adequate concentrations of therapeutic agents at the desired site of action, leading to systemic side effects and reduced efficacy. Nanoparticles, due to their small size and large surface area, can be engineered to overcome these limitations by providing targeted, controlled, and sustained release of drugs[37].

One of the most widely studied approaches for targeted drug delivery in obesity and diabetes is the use of lipid-based nanoparticles, such as liposomes and solid lipid nanoparticles (SLNs). These particles can encapsulate hydrophobic drugs, protecting them from degradation and enhancing their bioavailability[38, 39]. Furthermore, the surface of these nanoparticles can be modified with targeting ligands, such as antibodies, peptides, or small molecules, that bind specifically to receptors overexpressed in adipose tissue or pancreatic β-cells.

Polymeric nanoparticles also hold significant promise for targeted drug delivery in obesity and diabetes therapy. These nanoparticles can be designed to release their cargo in response to specific stimuli, such as changes in pH or temperature, ensuring that drugs are released only when they reach the desired site. Additionally, the surface

of these nanoparticles can be functionalized with targeting moieties to enhance their specificity for particular tissues or cells involved in the obesity–diabetes crosstalk[40–43].

Recent advances in nanotechnology have also led to the development of multifunctional nanoparticles capable of carrying multiple therapeutic agents. For instance, a single nanoparticle could simultaneously deliver anti-inflammatory drugs, insulin-sensitizing agents, and adipogenesis inhibitors, providing a comprehensive approach to treating obesity-related diabetes. This ability to target multiple pathways with a single nanosystem is a significant advantage over traditional therapies that typically focus on a single mechanism.

Biomolecular Modulation via Nanomaterials

Nanomaterials can be engineered to modulate biomolecular pathways involved in the obesity–diabetes crosstalk, providing a means of influencing gene expression and cellular behavior at the molecular level. For example, nanomaterials such as carbon nanotubes, gold nanoparticles, and mesoporous silica nanoparticles have been shown to interact with various biomolecules, including proteins, lipids, and nucleic acids, to modulate cellular signaling pathways involved in inflammation, insulin resistance, and adiposity[44, 45].

One of the most promising applications of nanomaterials for biomolecular modulation is the delivery of small RNA molecules, such as siRNA and miRNA, to inhibit the expression of genes involved in the pathogenesis of obesity and diabetes[46]. For example, siRNA targeting inflammatory cytokines like TNF-α and IL-6 has been shown to reduce insulin resistance and improve glucose metabolism in preclinical models. Similarly, miRNAs that regulate adipogenesis, such as miR-27 and miR-33, can be delivered using nanomaterials to inhibit fat cell differentiation and reduce obesity[46].

Nanomaterials can also be used to deliver small molecule inhibitors that target key enzymes involved in glucose metabolism, such as glucokinase or AMP-activated protein kinase (AMPK). By modulating these enzymes, nanomaterials can help to restore normal glucose homeostasis and improve insulin sensitivity[47]. Furthermore, nanomaterials can be designed to interact with specific receptors or proteins involved in cellular signaling, providing a means of modulating cellular processes such as autophagy, apoptosis, and oxidative stress. Through the precise modulation of biomolecular pathways, nanomaterials offer a novel approach to treating obesity and diabetes by targeting the molecular drivers of disease.

Clinical Prospects and Challenges in Nanomedicine for Obesity–Diabetes Therapy

While nanotechnology holds tremendous promise for treating obesity and diabetes, several challenges remain in translating these therapies from the laboratory to the clinic. One of the major obstacles is the potential toxicity of nanomaterials, which may accumulate in organs and tissues over time, leading to adverse effects. Regulatory agencies, such as the FDA, are still in the process of developing guidelines for the safety and approval of nanomedicines, which could slow the pace of clinical translation[48].

Another challenge is the complexity of the obesity–diabetes crosstalk, which involves multiple interconnected pathways that may require a multifaceted therapeutic approach. Nanomedicine may offer a solution by enabling the simultaneous targeting of multiple molecular targets within a single treatment, but this requires careful design and optimization of nanomaterials to ensure they are both effective and safe[49].

Additionally, the clinical efficacy of nano-enabled therapies will depend on factors such as patient variability, disease stage, and the specific characteristics of the nanomaterials used. For example, patients with advanced obesity-related diabetes may require more aggressive treatments than those with early-stage disease. Moreover, the long-term effects of nanomaterials on human health remain largely unknown, and further studies are needed to evaluate their safety and efficacy in human clinical trials.

Despite these challenges, the future of nanomedicine in obesity and diabetes therapy remains promising. Ongoing research and clinical trials are expected to yield valuable insights into the potential of nano-enabled strategies for treating these conditions, and the integration of nanotechnology with existing therapeutic modalities could revolutionize the management of obesity-related diabetes.

REFERENCES

1. Patra, D., Banerjee, D., Ramprasad, P., Roy, S., Pal, D., Dasgupta, S.: Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes. Front. Mol. Biosci. 10, 1224982 (2023). https://doi.org/10.3389/fmolb.2023.1224982
2. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
3. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
4. Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
5. De Sousa-Coelho, A.L., Estêvão, M.D., Patti, M.E., Lerin, C.: Editorial: Tissue crosstalk in obesity and diabetes: a focus on skeletal muscle. Front. Endocrinol. 16, 1724016. https://doi.org/10.3389/fendo.2025.1724016

6. Oh, K.-J., Lee, D.S., Kim, W.K., Han, B.S., Lee, S.C., Bae, K.-H.: Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. Int. J. Mol. Sci. 18, (2016). https://doi.org/10.3390/ijms18010008
7. Pillon, N.J., Loos, R.J.F., Marshall, S.M., Zierath, J.R.: Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. Cell. 184, 1530–1544 (2021). https://doi.org/10.1016/j.cell.2021.02.012
8. Čolak, E., Pap, D.: The role of oxidative stress in the development of obesity and obesity-related metabolic disorders. J. Med. Biochem. 40, 1–9 (2021). https://doi.org/10.5937/jomb0-24652
9. Bocarsly, M.E.: Pharmacological interventions for obesity: current and future targets. Curr. Addict. Rep. 5, 202–211 (2018). https://doi.org/10.1007/s40429-018-0204-0
10. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
11. De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
12. Omang, W.A., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
13. Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
14. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
15. Dutta, A., Paul, S.: Advancement in exosome-based cancer therapeutics: A new era in cancer treatment. Front. Nanotechnol. 4, (2022). https://doi.org/10.3389/fnano.2022.939197
16. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
17. Sibuyi, N.R.S., Moabelo, K.L., Meyer, M., Onani, M.O., Dube, A., Madiehe, A.M.: Nanotechnology advances towards development of targeted-treatment for obesity. J. Nanobiotechnology. 17, 122 (2019). https://doi.org/10.1186/s12951-019-0554-3
18. Xu, M., Zhang, X., Yu, X., Ma, C., Li, X., Chen, G., Yuan, G., Lin, S., Cui, R.: Epigenetic and metabolic reprogramming via nanotechnology: a synergistic approach to cancer vaccination in lung tumors. Front. Genet. 16, 1666561 (2025). https://doi.org/10.3389/fgene.2025.1666561
19. Zhang, M., Liu, E., Cui, Y., Huang, Y.: Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol. Med. 14, 212–227 (2017). https://doi.org/10.20892/j.issn.2095-3941.2017.0054
20. Anand, S., Patel, T.N.: Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review. Discov. Oncol. 15, 779 (2024). https://doi.org/10.1007/s12672-024-01662-1
21. Rabiee, A., Hossain, M.A., Poojari, A.: Adipose Tissue Insulin Resistance: A Key Driver of Metabolic Syndrome Pathogenesis. Biomedicines. 13, 2376 (2025). https://doi.org/10.3390/biomedicines13102376
22. Elkanawati, R.Y., Sumiwi, S.A., Levita, J.: Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies. Drug Des. Devel. Ther. 18, 3337–3360 (2024). https://doi.org/10.2147/DDDT.S468147
23. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
24. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., Ostolaza, H., Martín, C.: Pathophysiology of Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 21, 6275 (2020). https://doi.org/10.3390/ijms21176275
25. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
26. Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., Tong, N.: Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct. Target. Ther. 9, 262 (2024). https://doi.org/10.1038/s41392-024-01951-9

27. Venturini, J., Chakraborty, A., Baysal, M.A., Tsimberidou, A.M.: Developments in nanotechnology approaches for the treatment of solid tumors. Exp. Hematol. Oncol. 14, 76 (2025). https://doi.org/10.1186/s40164-025-00656-1
28. Aljabali, A.A.A., Obeid, M.A., Gammoh, O., El-Tanani, M., Mishra, V., Mishra, Y., Kapre, S., Palakurthi, S.S., Hassan, S.S., Nawn, D., Lundstrom, K., Hromić-Jahjefendić, A., Serrano-Aroca, Á., Redwan, E.M., Uversky, V.N., Tambuwala, M.M.: Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions. Cancers. 16, (2024). https://doi.org/10.3390/cancers16112030
29. Gholami, A., Mohkam, M., Soleimanian, S., Sadraeian, M., Lauto, A.: Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy. Microsyst. Nanoeng. 10, 1–43 (2024). https://doi.org/10.1038/s41378-024-00743-z
30. Unnisa, A., Greig, N.H., Kamal, M.A.: Nanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer's disease. Neural Regen. Res. 18, 2127–2133 (2023). https://doi.org/10.4103/1673-5374.369096
31. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ. J. Basic Appl. Sci. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
32. Mohite, P., Singh, S., Pawar, A., Sangale, A., Prajapati, B.G.: Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Front. Drug Deliv. 3, (2023). https://doi.org/10.3389/fddev.2023.1232012
33. Yun, Y., An, J., Kim, H.J., Choi, H.K., Cho, H.-Y.: Recent advances in functional lipid-based nanomedicines as drug carriers for organ-specific delivery. Nanoscale. (2025). https://doi.org/10.1039/D4NR04778H
34. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
35. Sun, Y., Yan, K., Zhang, Y., Han, Y.-Q., Hao, L.-H., Gao, Y., Wang, H.-L., Chu, H.-Q., Ye, J., Liu, Y.-L., Yang, Y.-F.: Advanced multifunctional nano-delivery platform focusing on treating diseases related to lipid metabolism via targeted intervention in various lipid metabolic processes. Mil. Med. Res. 12, 87 (2025). https://doi.org/10.1186/s40779-025-00672-6
36. Zhang, K., Yang, X., Zhao, Q., Li, Z., Fu, F., Zhang, H., Zheng, M., Zhang, S.: Molecular Mechanism of Stem Cell Differentiation into Adipocytes and Adipocyte Differentiation of Malignant Tumor. Stem Cells Int. 2020, 8892300 (2020). https://doi.org/10.1155/2020/8892300
37. Luo, X., Li, N., Zhu, X., Xie, W., Zhang, Q., Liang, N., Zhang, P., Zhou, C.: Application of nanomaterials in diabetic complication management. Colloids Surf. B Biointerfaces. 258, 115229 (2026). https://doi.org/10.1016/j.colsurfb.2025.115229
38. Nanomedicines for precise therapy in hyperlipidemia and obesity. In: Nanobiomaterials and Nanomedicines for Metabolic Disorders. pp. 305–374. Elsevier (2026)
39. Liu, M., Wang, R., Hoi, M.P.M., Wang, Y., Wang, S., Li, G., Vong, C.T., Chong, C.-M.: Nano-Based Drug Delivery Systems for Managing Diabetes: Recent Advances and Future Prospects. Int. J. Nanomedicine. 20, 6221–6252 (2025). https://doi.org/10.2147/IJN.S508875
40. Eltaib, L.: Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers. 17, (2025). https://doi.org/10.3390/polym17070833
41. Herdiana, Y., Wathoni, N., Shamsuddin, S., Muchtaridi, M.: Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano. 7, 100048 (2022). https://doi.org/10.1016/j.onano.2022.100048
42. Zhang, H., Chen, H., Hu, X., Muhammad, W., Liu, C., Liu, W.: Inflammation-modulating polymeric nanoparticles: design strategies, mechanisms, and therapeutic applications. eBioMedicine. 118, 105837 (2025). https://doi.org/10.1016/j.ebiom.2025.105837
43. Zielińska, A., Carreiró, F., Oliveira, A.M., Neves, A., Pires, B., Venkatesh, D.N., Durazzo, A., Lucarini, M., Eder, P., Silva, A.M., Santini, A., Souto, E.B.: Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules. 25, 3731 (2020). https://doi.org/10.3390/molecules25163731
44. Lu, H., Liu, Z., Wang, Y., Casals, E., Hanzu, F.A., Morales-Ruiz, M., Zeng, M., Casals, G.: Endocrine nanozymology: Nanozyme applications in diabetes, obesity, and hormonal disorders. Theranostics. 16, 712–735 (2026). https://doi.org/10.7150/thno.122577
45. Ma, J., Yang, S., Yang, Z., He, Z., Du, Z.: Functional Nanomaterials for Advanced Bioelectrode Interfaces: Recent Advances in Disease Detection and Metabolic Monitoring. Sensors. 25, (2025). https://doi.org/10.3390/s25144412
46. Rinoldi, C., Zargarian, S.S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., De Sio, L., Gualandi, C., Ding, B., Pierini, F.: Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines. Small Methods. 5, 2100402 (2021). https://doi.org/10.1002/smtd.202100402

47. Yadav, K., Singh, D., Singh, M.R., Pradhan, M.: Nano-constructs targeting the primary cellular energy source of cancer cells for modulating tumor progression. OpenNano. 8, 100107 (2022). https://doi.org/10.1016/j.onano.2022.100107
48. Vallianou, N.G., Dalamaga, M., Pavlou, A., Rebelos, E., Karamanolis, N.N., Papachristoforou, E., Mavrothalassitis, E., Eleftheriadou, I., Tentolouris, N., Kounatidis, D.: The Transformative Role of Nanotechnology in the Management of Diabetes Mellitus: Insights from Current Research. Biomolecules. 15, (2025). https://doi.org/10.3390/biom15050653
49. Sun, Y., Yan, K., Zhang, Y., Han, Y.-Q., Hao, L.-H., Gao, Y., Wang, H.-L., Chu, H.-Q., Ye, J., Liu, Y.-L., Yang, Y.-F.: Advanced multifunctional nano-delivery platform focusing on treating diseases related to lipid metabolism via targeted intervention in various lipid metabolic processes. Mil. Med. Res. 12, 87 (2025). https://doi.org/10.1186/s40779-025-00672-6

CITE AS: Taliikwa Nicholas Ceaser (2026). Nano-Enabled Strategies for Targeting Obesity–Diabetes Crosstalk: Therapeutic Innovations and Clinical Prospects. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):63-68. https://doi.org/10.59298/IDOSRJSR/2026/11.2.6368